Acuta Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-76,100
| Closed | -$4.56M | – | 35 |
|
|
2023
Q4 | $4.56M | Sell |
76,100
-168,384
| -69% | -$10.1M | 2.56% | 18 |
|
|
2023
Q3 | $9.3M | Sell |
244,484
-53,112
| -18% | -$2.02M | 6.23% | 2 |
|
|
2023
Q2 | $27.1M | Buy |
297,596
+7,096
| +2% | +$646K | 18.37% | 1 |
|
|
2023
Q1 | $19.2M | Buy |
290,500
+73,000
| +34% | +$4.82M | 14.12% | 1 |
|
|
2022
Q4 | $11.2M | Sell |
217,500
-336,500
| -61% | -$17.4M | 6.92% | 3 |
|
|
2022
Q3 | $37.8M | Hold |
554,000
| – | – | 16.29% | 1 |
|
|
2022
Q2 | $25.1M | Hold |
554,000
| – | – | 13.96% | 1 |
|
|
2022
Q1 | $28.1M | Buy |
554,000
+19,000
| +4% | +$965K | 13.15% | 1 |
|
|
2021
Q4 | $25.3M | Buy |
535,000
+459,500
| +609% | +$21.7M | 10.63% | 2 |
|
|
2021
Q3 | $2.49M | Sell |
75,500
-85,000
| -53% | -$2.8M | 0.88% | 31 |
|
|
2021
Q2 | $10.1M | Buy |
160,500
+47,339
| +42% | +$2.99M | 4.05% | 3 |
|
|
2021
Q1 | $4.86M | Sell |
113,161
-53,893
| -32% | -$2.31M | 1.75% | 26 |
|
|
2020
Q4 | $9.56M | Hold |
167,054
| – | – | 2.6% | 14 |
|
|
2020
Q3 | $5.04M | Sell |
167,054
-22,946
| -12% | -$692K | 1.37% | 24 |
|
|
2020
Q2 | $6.21M | Sell |
190,000
-19,500
| -9% | -$637K | 1.79% | 24 |
|
|
2020
Q1 | $5.61M | Buy |
209,500
+22,000
| +12% | +$589K | 2.72% | 15 |
|
|
2019
Q4 | $5.74M | Buy |
+187,500
| New | +$5.74M | 1.42% | 19 |
|
|
2018
Q3 | – | Sell |
-168,000
| Closed | -$3.7M | – | 24 |
|
|
2018
Q2 | $3.7M | Buy |
+168,000
| New | +$3.7M | 0.66% | 24 |
|